3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
58
Lymphoma, Large B-Cell, Diffuse
25
Lymphoma, Follicular
23
Lymphoma
18
Leukemia, Lymphocytic, Chronic, B-Cell
17
Recurrence
16
Lymphoma, Non-Hodgkin
14
Lymphoma, Mantle-Cell
14
Lymphoma, B-Cell, Marginal Zone
12
Lymphoma, B-Cell
10
Neoplasms, Plasma Cell
9
Waldenstrom Macroglobulinemia
6
Hodgkin Disease
6
Neoplasms
5
Leukemia, Myeloid, Acute
5
Burkitt Lymphoma
5
Lymphoma, T-Cell
4
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Myelodysplastic Syndromes
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, Large-Cell, Anaplastic
3
Leukemia
3
Hematologic Neoplasms
3
Sezary Syndrome
2
Paraproteinemias
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Mycosis Fungoides
2
Lymphoma, Large-Cell, Immunoblastic
2
Interventions
Cyclophosphamide
4
fludarabine
3
Bendamustine Hydrochloride
3
ibrutinib
2
fludarabine phosphate
2
Bortezomib
2
ponatinib
1
enzalutamide
1
durvalumab
1
Rituximab
1
Lenalidomide
1
KW-2478
1
Hsp90 inhibitor KU757
1
CA-4948
1
Busulfan
1
ARQ531
1
AP 1903 reagent
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Immune System Diseases
×
Lenalidomide
×
Clear all
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts